Cargando…

Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience

INTRODUCTION: We conducted this study to reflect a single-center experience with the use of neoadjuvant systemic chemotherapy (NAC) for the management of women with operable breast cancer. METHODS: We conducted a retrospective chart review on all women presenting with operable, stage II–III, breast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaher, Haidi Abd El, Fathy, Hamada, Abozeid, Mohamed, Faisal, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559473/ https://www.ncbi.nlm.nih.gov/pubmed/37805553 http://dx.doi.org/10.1186/s12957-023-03199-z

Ejemplares similares

Role of the triad of procalcitonin, C-reactive protein, and white blood cell count in the prediction of anastomotic leak following colorectal resections
por: El Zaher, Haidi Abd, et al.
Publicado: (2022)

Correction to: Role of the triad of procalcitonin, C-reactive protein, and white blood cell count in the prediction of anastomotic leak following colorectal resections
por: El Zaher, Haidi Abd, et al.
Publicado: (2022)

Effect of autologous fibrin glue on seroma reduction after modified radical mastectomy for breast cancer: A randomized controlled trial()
por: Faisal, Mohammed, et al.
Publicado: (2021)

Breast cancer involvement of the nipple-areola complex and implications for nipple-sparing mastectomies: a retrospective observational study in 137 patients
por: Faisal, Mohammed, et al.
Publicado: (2019)

Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer
por: White, Rohen, et al.
Publicado: (2016)

Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy
por: TAKAHASHI, RYUJI, et al.
Publicado: (2013)

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
por: Yao, Yuanshan, et al.
Publicado: (2022)

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study
por: Zhang, Xuchen, et al.
Publicado: (2023)

Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
por: Yang, Yaewon, et al.
Publicado: (2016)

Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer
por: Zhang, Meng, et al.
Publicado: (2023)

Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
por: Brain, E., et al.
Publicado: (1997)

Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy
por: Wu, San-Gang, et al.
Publicado: (2015)

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer
por: López-Vega, José Manuel, et al.
Publicado: (2021)

An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Chung, Wai-Shan, et al.
Publicado: (2022)

Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial
por: Yang, Ciqiu, et al.
Publicado: (2022)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II–III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy
por: Chen, Xingxing, et al.
Publicado: (2018)

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2‐Positive Breast Cancer: A Phase II Clinical Trial
por: Xuhong, Juncheng, et al.
Publicado: (2020)

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies
por: Vriens, Birgit E.P., et al.
Publicado: (2017)

Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy
por: Brun, Jean-Luc, et al.
Publicado: (2009)

Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities
por: Curtis, Kelly K, et al.
Publicado: (2011)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007)

Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma
por: Aryan, Mahmoud, et al.
Publicado: (2021)

Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
por: Sinn, K., et al.
Publicado: (2022)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
por: Lang, Julie E., et al.
Publicado: (2022)

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)
por: Ferreira, Arlindo R., et al.
Publicado: (2018)

Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer
por: Zhu, Jun, et al.
Publicado: (2017)

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
por: Muñoz-Guglielmetti, Diego, et al.
Publicado: (2021)

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
por: Zhu, Xinsheng, et al.
Publicado: (2022)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

Immunoscore(®) as a predictor of response to chemotherapy in stage II and stage III colon cancer
por: Mlecnik, Bernhard, et al.
Publicado: (2015)

Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience
por: Gao, Tian, et al.
Publicado: (2019)

The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB
por: Liu, Jieqiong, et al.
Publicado: (2015)

Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era
por: Nakajima, Naomi, et al.
Publicado: (2018)

Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini’s Mean Difference of Restricted Mean Survival Times
por: Keam, Bhumsuk, et al.
Publicado: (2021)

Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer
por: Dong, Menghao, et al.
Publicado: (2022)

Letter re: Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
por: Zhang, J., et al.
Publicado: (2022)

Individualized Concurrent Chemotherapy for Patients with Stage III–IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy
por: Ji, Pengjie, et al.
Publicado: (2023)

Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy
por: Jin, Hailong, et al.
Publicado: (2013)

A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV
por: Dai-yuan, Ma, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r3fk2b8j9hnh99ejf89nsvk945